The 2015-2017 epidemics of Zika virus (ZIKV) in the Americas caused widespread protective 9 immunity. The timing and burden of the next Zika virus outbreak remains unclear. We used an 10 agent-based model to simulate the dynamics of age-specific immunity to ZIKV, and predict the 11 future age-specific risk using data from Managua, Nicaragua. We also investigated the potential 12 impact of a ZIKV vaccine. Assuming lifelong immunity, the risk of a ZIKV outbreak will remain 13 low until 2035 and rise above 50% in 2047. The imbalance in age-specific immunity implies that 14 people in the 15-29 age range will be at highest risk of infection during the next ZIKV outbreak, 15 increasing the expected number of congenital abnormalities. ZIKV vaccine development and 16 licensure are urgent to attain the maximum benefit in reducing the population-level risk of 17 infection and the risk of adverse congenital outcomes. This urgency increases if immunity is not 18 lifelong.
in order to compute the weekly incidence on week t: 135 We fitted the model to weekly incidence data A using a normal likelihood after a square-root 136 variance-stabilizing transformation (Guan, 2009):
where ρ is a reporting rate parameter and σ an error parameter. In addition, we also fitted the 139 model to the number of individuals with anti-ZIKV antibodies at the end of the epidemic by age 140 group B a using a binomial likelihood:
where B a the number of individuals with antibodies, n a is the sample size in each age group, and p a = R a (t end )/N a (t end ) the proportion of immune at the end of the epidemic. The full likelihood 144 was obtained by multiplying Eq. 6 and Eq. 7. We chose weakly-informative priors for all parameters 145 and fitted the model in Stan ( 151 We used the deterministic model, described in the previous section, to infer the proportion of people 152 with protective immunity within each age group at the end of the 2016 epidemicp a . We used one 153 thousand posterior samples ofp a in the ABM to allow the propagation of uncertainty. Protective 154 immunity to ZIKV after infection was lifelong in our first scenario, so the reduction of the overall 155 proportion of immune individuals in the population decreased only because of population renewal.
ZIKV immunity

156
Given the absence of evidence about the duration of immunity to ZIKV, we considered four scenarios 157 assuming exponentially distributed durations of immunity with means of 30, 60, 90, or 150 years.
158
These values correspond to a proportion of initially immune agents that loses immunity after 10 159 years of 28%, 15%, 11% or 6%, respectively (Appendix A.3). The ageing process was linear, increasing the age of each agent by 7 days at each 7-day time step. 167 2.3.4 ZIKV reintroduction 168 We reintroduced ZIKV in the population after a delay of d = {1, · · · , 80} years in independent 169 simulations. We chose this approach rather than continuous reintroductions to remove some of 170 the stochasticity and assess more clearly the association between immunity decay and risk of an 171 outbreak. As the probability of an extinction of the outbreak depends on the number of ZIKV cases reintroduced in the population, we considered three different values for the seed (1, 5 or 10 cases) and compared the results (Appendix A.4). Simulations using continuous reintroductions each year
Risk of adverse congenital outcomes
on the exposure, i.e. the number of pregnant women infected by ZIKV during their first trimester, 15-49 years from ABM simulations. As gender was not explicitly considered in the model, we 181 assumed that women represented 50% of the population. We assumed a uniform distribution of 182 births during the reproductive period, and considered that the first trimester constituted a third 183 of ongoing pregnancies at a given time. We explored three different levels of risk of microcephaly 
Immunity and population 212
In our forward simulations, the expected population size increased by 42% between 2017 and 2097.
213
Under the assumption that ZIKV infection results in lifelong protective immunity, population re-214 newal will create an imbalance in the proportion immune in different age groups. We expect the 215 overall proportion of the population with protective immunity to have halved (from 48% to 24%) 216 by 2051 and to be concentrated among the older age classes ( Fig. 2A) . The 0-14 year old age group 217 will become entirely susceptible by 2031 and the 15-29 year old age group by 2046. (Fig. 2B ). After this point, attack rates resulting from ZIKV reintroduction will rise steeply.
222
By 2047, we predict that ZIKV reintroductions will have a 50% probability of resulting in outbreaks 223 with attack rates greater than 1% (Fig. 2C) . 
Risk of infection and microcephaly births in women of reproductive
225 age 226 The differences between age groups in both immunity and transmission will result in a dispropor-227 tionate burden of infection in the 15-29 age class. The relative risk of infection in this age group 228 ranges from 1.2 to 1.6, compared with the general population if an outbreak occurs during the pe-229 riod 2032-2075 ( Fig. 3A) . As most pregnancies occur in this age group, these women are also the 230 most likely to experience a pregnancy with an adverse outcome. The increased risk of infection in 231 this group implies that the number of adverse congenital outcomes resulting from a ZIKV outbreak 232 during this period is likely to be higher than expected with a homogeneous distribution of immunity 233 across ages. Assuming different values for the added risk of microcephaly after a ZIKV infection 234 during the first trimester, we expect the mean number of additional microcephaly cases due to ZIKV 235 infection resulting from the reintroduction of the virus in Managua, Nicaragua to reach 1 to 5 cases 236 per 100,000 population in 2060 ( Fig. 3B ). 
Loss of immunity 238
If protective immunity to ZIKV is not lifelong, the time window before observing a rise in the attack 239 rates resulting from ZIKV reintroduction will shorten (Fig. 4A ). For instance, if 15% of the those as it becomes more difficult to maintain the herd immunity (Fig. 5B) . From systematic review to living systematic review. F1000Research. 2018 7(196) We used the next generation matrix method described by Diekmann et al. to calculate R 0 (eq. 8 527 -10). β 1 is the transmission rate for the 0-14 age group; β 2 for the >15 group; γ is the common 528 recovery rate.
A.3 Loss of immunity scenarios 530 We explored plausible scenarios of loss of immunity (Fig. A.1) . Using the ABM (model B) we explored the effect of yearly introduction of one infectious individual 539 in the population (n=10,000). In the main text, we assumed a single introduction of n individuals 540 per simulation. Here we introduce on a yearly basis the infectious individuals; previous outbreaks 541 during the simulation affect the likelihood of a next outbreak and observed patterns are more 542 stochastic. However, the pattern of the attack rate over time remains similar to the findings of the 543 once/simulation introduction (Fig. A.3) ; the variation is larger due to a more stochasticity. of the more complex models does not outperform the fit of the simplest (SIR) model ( 
